Table 2– Concentrations of desmosines in relation to baseline characteristics of the study cohort
U-desmosines nmol·mmol−1 creatinineP-desmosines nmol·L−1
Subjects nMedian (range)Subjects nMedian (range)
Sex
 Males1282.2 (1.3–6.0)1220.47 (0.16–1.3)
 Females2212.8 (1.5–5.7)1960.48 (0.28–1.4)
Age yrs
 46–551042.2 (1.4–4.1)980.41 (0.16–0.76)
 55–59832.4 (1.3–4.2)750.43 (0.28–0.87)
 60–64772.8 (1.8–5.2)720.51 (0.32–1.3)
 65–69413.0 (1.7–6.0)340.58 (0.37–1.1)
 70–87443.7 (2.3–5.7)390.71 (0.41–1.4)
Smoking habit
 Current smokers692.7 (1.5–6.0)610.51 (0.16–1.3)
 Occasional smokers202.5 (1.5–4.0)200.47 (0.31–0.68)
 Ex-smokers1462.6 (1.4–5.2)1380.48 (0.28–1.2)
 Never-smokers1142.5 (1.3–5.7)990.46 (0.28–1.4)
BMI kg·m−2
 <251872.5 (1.4–6.0)1700.46 (0.16–1.3)
 25–301312.7 (1.3–5.7)1200.48 (0.28–1.4)
 ≥30312.9 (1.9–5.0)280.53 (0.37–1.3)
Disease severity#
 No disease2342.5 (1.3–5.7)2120.46 (0.16–1.4)
 GOLD I672.6 (1.5–5.0)610.49 (0.30–1.3)
 GOLD II432.9 (1.7–6.0)400.55 (0.33–1.2)
 GOLD III52.8 (2.0–4.1)50.64 (0.47–1.1)
  • BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease. #: defined in [16] as GOLD I (mild), forced expiratory volume in 1 s (FEV1) ≥80% predicted; GOLD II (moderate), FEV1 <80 and ≥50% pred; GOLD III (severe) FEV1 <50 and ≥30% pred; GOLD IV (very severe), FEV1 <30% pred.